BeiGene: Novartis Grabs Tislelizumab Rights
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...
420 Views
New Horizon Health IPO Initiation: Screening for Cancer
New Horizon will have a listing hearing for a $300 million HK IPO this week. We believe that New Horizon has the right ingredients to capitalise on...
621 Views
Eddingpharm: First Impressions
Eddingpharm plans to list on the HKEX. This Insight analyzes the company's products and pipeline. The main question is whether enthusiasm for the...
576 Views
Cansino Biologics Placement - Past Deal Didn't Do Well, Losing the Vaccine Race
Lilly Asia is looking to raise around US$180m via selling a 6% stake in CanSino Biologics Inc (6185 HK)'sĀ H-shares. Lilly Asia last sold its stake...
615 Views
